Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nitracrine and its congeners--an overview

M Gniazdowski1, L Szmigiero

  • 1Department of General Chemistry, Medical University in Lódź, Poland.

General Pharmacology
|May 1, 1995
PubMed
Summary

Nitracrine (C-283) is an anticancer drug that effectively interacts with DNA, leading to cytostatic effects. Its activation involves nitro group reduction, resulting in covalent DNA binding and crosslinking, with selective toxicity observed in hypoxic cells.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular disease risk factors associated with low level of physical activity in postmenopausal Polish women.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2013
Same author

ADRB3 and PPARγ2 gene polymorphisms and their association with cardiovascular disease risk in postmenopausal women.

Climacteric : the journal of the International Menopause Society·2012
Same author

Cytotoxicity, cellular uptake and DNA damage by daunorubicin and its new analogues with modified daunosamine moiety.

Cell biology and toxicology·2005
Same author

Inhibition of RNA synthesis in vitro and cell growth by anthracycline antibiotics.

Neoplasma·2002
Same author

Effects of anticancer drugs on transcription in vitro.

Zeitschrift fur Naturforschung. C, Journal of biosciences·2001
Same author

Transcription factors as targets of anticancer drugs.

Acta biochimica Polonica·1999

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Cancer Research

Background:

  • Nitracrine (C-283) is an acridine derivative with potent anticancer properties.
  • Its cytostatic effects are linked to interactions with DNA, a critical target in cancer therapy.

Purpose of the Study:

  • To investigate the mechanism of nitracrine's interaction with DNA.
  • To understand the role of nitro group reduction in drug activation and DNA binding.
  • To evaluate nitracrine's potential for radiosensitization in hypoxic cells.

Main Methods:

  • Examination of DNA-drug non-covalent and covalent interactions in model systems.
  • Analysis of nitracrine derivatives with modified structures.
  • Detection of DNA-protein and interstrand crosslinks in treated cells.

Main Results:

  • Nitracrine's nitro group reduction is crucial for its covalent binding to DNA and proteins.
  • The drug forms both non-covalent and covalent complexes with DNA.
  • DNA-protein crosslinks and interstrand crosslinks were observed in cells exposed to nitracrine.
  • Nitracrine demonstrated selective toxicity and radiosensitization effects on hypoxic mammalian cells.

Conclusions:

  • Nitracrine's anticancer activity is mediated by its interaction with DNA, involving covalent binding and crosslinking.
  • Nitro group reduction is a key activation step for nitracrine's DNA-damaging effects.
  • Nitracrine shows promise as a radiosensitizer for hypoxic tumors due to its selective toxicity.

Related Experiment Videos